Clinical Trials

875 enrolled

Leukemia, Myeloid, Acute

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

22 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT06918431 2026-03-17

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

53 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

24 enrolled

Leukemia, Myeloid, Acute

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Lymphoid

Burkitt Lymphoma

NCT06289673 2026-03-03

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Phase 4 Recruiting

850 enrolled

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

240 enrolled

Leukemia, Myeloid, Acute

NCT06390319 2026-02-27

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

100 enrolled

Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03629171 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

21 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT06533748 2026-02-12

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

128 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07228273 2026-01-22

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

MyeloidOther hematologic neoplasm

102 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05342584 2026-01-08

Venetoclax AML

MyeloidOther hematologic neoplasm

99 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT07232134 2025-11-20

AML-DS-2025

100 enrolled

Down Syndrome, Leukemia, Myeloid, Acute

NCT06451861 2025-11-17

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

240 enrolled

Leukemia, Myeloid, Acute

NCT04801797 2025-11-14

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

172 enrolled

Leukemia, Myeloid, Acute

NCT07152041 2025-09-03

CAMS-Ph+ B-ALL

150 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06855810 2025-08-26

CCCG-TALL-2025

Phase 2/3 Recruiting

610 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06882057 2025-08-26

CCCG-LR-B-ALL

Phase 2/3 Recruiting

3,000 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04440267 2025-08-06

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

50 enrolled

Leukemia, Biphenotypic, Acute

NCT05660473 2025-08-01

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

100 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07078591 2025-07-28

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

50 enrolled

Leukemia, Myeloid, Acute

NCT07008638 2025-07-09

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Recruiting

32 enrolled

Leukemia, Myeloid, Acute

NCT05959720 2025-05-07

BRALLA

Recruiting

180 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03643276 2025-04-06

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

5,000 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04043494 2025-03-21

LBL 2018

683 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

50 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT05832320 2024-05-10

Optimum Induction Therapy of Low-risk APL

Phase NA Recruiting

74 enrolled

Leukemia, Promyelocytic, Acute

NCT05939180 2024-04-09

VA vs DA for Newly Diagnosed Hig-risk AML

Phase 2/3 Recruiting

116 enrolled

Leukemia, Myeloid, Acute

NCT03286634 2022-09-28

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

60 enrolled

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02724163 2021-10-08

Myechild01

700 enrolled